Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13905109 | 1.00 | LMNA (0.30) | LMNATHRBSMN1; SMN2HIF1A | |
| SCHEMBL3948809 | 0.94 | LMNA (0.32) | LMNATHRBSMN1; SMN2HIF1A | |
| SCHEMBL4020116 | 0.94 | LMNA (0.32) | LMNATHRBSMN1; SMN2HIF1A | |
| SCHEMBL13906749 | 0.94 | LMNA (0.32) | LMNATHRBSMN1; SMN2HIF1A | |
| SCHEMBL13906778 | 0.93 | CCNT1 (0.31) | — | |
| SCHEMBL3959198 | 0.93 | CCNT1 (0.31) | — | |
| SCHEMBL3953317 | 0.91 | CCNT1 (0.30) | — | |
| SCHEMBL13906779 | 0.91 | CCNT1 (0.30) | — | |
| SCHEMBL3946173 | 0.89 | RIPK2 (0.32) | HIF1A | |
| SCHEMBL13906800 | 0.89 | RIPK2 (0.32) | HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009029729-A1 | AMINO TRICYCLIC-NUCLEOSIDE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. (US) | 2009-03-05 | — | — | WO | claimed |
| US-20090062223-A1 | AMINO TRICYCLIC-NUCLEOSIDE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. | 2009-03-05 | — | — | US | claimed |
| WO-2009029729-A1 | AMINO TRICYCLIC-NUCLEOSIDE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| US-20090062223-A1 | AMINO TRICYCLIC-NUCLEOSIDE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062223-A1 | AMINO TRICYCLIC-NUCLEOSIDE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | PNP, SLC29A1, SLC28A1 | LMNA 710/4885THRB 4060/4885SMN1; SMN2 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.